Leitat projects €48M in 2023 revenue, with 20% from R&D. Its health division, founded in 2009, specializes in therapies and health predictors, focusing on personalized medicine...
Leitat has strengthened its biotechnology focus by acquiring ReadyCell via MedTech Barcelona. This acquisition boosts Leitat's role in developing advanced cell kits for in vitro testing,...